NeoStem Covered by AOL’s Daily Finance Website – Vatican Investing $1 Million to Further NeoStem’s Stem Cell Development

NesoStem, Inc. was covered prominently this morning on the AOL Finance website in an article discussing the Vatican’s involvement in NeoStem’s VSEL (very small embryonic like) stem cell research. We have included the first part of the article below along with a link to the full article.

Inside Wall Street: This Tiny Stem Cell Biotech Has the Vatican’s Backing

By GENE MARCIAL Posted 7:30 AM 03/07/11 

 

The fiery subject of medicine based on human stem cells usually evokes roiling controversy, often generating more questions than answers. So, stem cell therapies have yet to catch on among investors — and on Wall Street. No wonder a tiny company like NeoStem (NBS), which focuses on stem cell research and its medical applications, continues to be underappreciated, if not ignored.

And yet it has attracted several big-name investors that are intrigued by some unexpected events, including the Catholic Church’s surprising embrace of NeoStem’s research and NeoStem’s foothold in China’s vast health care market. The Vatican has decided to invest $1 million in NeoStem, a biopharmaceutical company developing proprietary cellular therapies. NeoStem is aiming to become a single source for the collection, storage and manufacture of adult stem cells — rather than embryonic stem cells from aborted fetuses — for cell-based medicine and regenerative science.

What’s the Vatican’s interest in NeoStem? In particular, the Church is very interested in the company’s work on adult stem cells, and what they imply on theological and philosophical grounds.

Read More

NeoStem Announces the Addition of Jason Kolbert as Vice President of Strategic Business Development

3/7/2011 7:00 AM – PR Newswire

NEW YORK, March 7, 2011 /PRNewswire via COMTEX News Network/ –

NeoStem, Inc. (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, is pleased to announce that Jason Kolbert has joined the firm as Vice President of Strategic Business Development. Jason was formerly a managing director of National Securities where he founded the firm’s research effort in emerging biotechnology companies. Jason’s coverage universe has been focused on cell therapeutic companies focused in oncology and regenerative medicine, where NeoStem was one of his covered companies.

Read More

NeoStem to Present at Cowen Healthcare Conference on March 7 and 8

NeoStem (NYSE-Amex: NBS) will present on a panel at the 31st Annual Cowen Group Health Care Conference. The panel discussion will take place on Monday, March 7, 2011 at 1 PM and Dr. Robin Smith, the Company’s Chairman and CEO, will present on Tuesday, March 8, 2011 at 10:15 AM. The Conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

Read More

NeoStem Analyst Report: Bridging the East and the West as a One-Stop Shop for Cellular Therapy

Rodman & Renshaw has initiated coverage of NeoStem, Inc. (NYSE-Amex: NBS) with a 12-month price target of $3.00 per share.  Below is an excerpt from the report, a complete copy of which is available here.

“NeoStem is comprised of three business units, each with its own value proposition, including: 1) pharmaceutical manufacturing and sales in China ($52 MM in sales in the first 3 quarters of 2010); 2) storage and development of adult stem cells for regenerative medicine in China and in the US; and 3) third party manufacturing of cellular therapies through the acquisition of Progenitor Cell Therapy (PCT, Private). We derive our valuation for NeoStem based on a sum of the parts analysis encompassing a comparables analysis for the regenerative medicine component and a P/S multiple analysis for the Chinese pharmaceutical component. Companies developing therapeutics in the regenerative medicine space are trading at an average enterprise value (EV) of $192 MM, from which we derive a price target of $2/share for the stem cell business. The estimated value of the pharmaceutical business is $1/share after applying an average 2.6X P/S multiple to our 2011 pharmaceutical sales estimates. Based on a sum-of-the-parts methodology, we derive a 12-month target price of $3/share for NeoStem.”

Complete Report

NeoStem Analyst Report Cites a $5 Price Target

In an updated anlayst report released this morning, Maxim Group reiterates its buy rating with a 12-month price target of $5.00 for NeoStem (NYSE-Amex: NBS).  According to the report, the Company’s stem cell operations have multiple revenue generating opportunities.  Yesterday, the Company announced the planned launch of its adult stem cell banking and cord blood banking programs, which will be bundled together as “Family Plan” in the U.S.

Read More

Q&A with NeoStem Chairman and CEO Dr. Robin Smith

Dr. Robin Smith, Chairman and CEO of NeoStem (NYSE-Amex: NBS) discusses the Company’s pharmaceutical and stem cell operations in connection with its recent acquisition of Progenitor as well as expectations for the next six to twelve months.  This interview can be seen by clicking on the picture below.

NeoStem CEO Dr. Robin Smith Interviewed

NeoStem (NYSE-Amex: NBS) Chief Executive Officer, Dr. Robin Smith, is interviewed about the Company’s generic pharmaceutical and stem cell business segments.

View Video

NeoStem to Present at 13th Annual BIO CEO & Investor Conference

NeoStem (NYSE-Amex: NBS) will present at the 2011 BIO CEO & Investor Conference which will take place February 14-15 at the Waldorf-Astoria in New York.  Dr. Robin Smith, MD, MBA, CEO of NeoStem, will present in the Duke of Windsor Room at 8 AM on Monday, February 14.

Dr. Smith will be discussing the Company’s accomplishments in 2010 and expectations for 2011, including the raising of more than $19 million in November 2010.  Funds raised will help the Company grow its revenue lines of businesses in the US and China, including the closing of our acquisition of Progenitor Cell Therapy LLC, and further assist in our growth.  NeoStem was also named “Best Stem Cell Company, 2010″ in The New Economy’s Biotech Awards.  Additionally, The Vatican’s Pontifical Council has undertaken to commit $1 million to joint ventures with NeoStem and the Stem for Life Foundation, a not-for-profit entity NeoStem participated in founding, to expand research and raise awareness of adult stem cell therapies.

NeoStem Acquires Progenitor Cell Therapy

NeoStem (NYSE: NBS) has completed the previously announced acquisition of Progenitor Cell Therapy, a privately held cell therapy company with operations on the East and West coasts of the U.S.  Progenitor serves the cell therapy community with cGMP state-of-the art cell therapy manufacturing facilities, and processing and storage facilities for stem cells collected from the umbilical cord at birth.

Progenitor’s revenue generating business will complement NeoStem’s growing adult stem cell operations and PCT’s management adds to NeoStem the over 100 years’ collective experience of the PCT management team in the business and science of cell therapy and its development.

According to Dr. Robin Smith, CEO of NeoStem, “The merger with PCT is a significant step toward NeoStem’s goal of becoming a leader in the fast-growing Stem Cell Industry, generating revenues, and developing and licensing therapies to be used in the United States and abroad.  addition of PCT will allow NeoStem to focus on growing the cord blood and adult stem cell banking, cellular manufacturing and therapeutic business, as well as expanding our businesses in Asia and other countries, while continuing to develop our intellectual property and acquire new technology.”

Read More

DoD Recommends Funding NeoStem $1.7 Million

NeoStem, Inc. (NYSE: NBS) will receive $1.7 million to employ the Company’s VSEL Technology, which uses very small embryonic-like stem cells, to treat osteoporosis and improve bone health. The Company will receive funds upon completion of the award process.

This is a big deal for NeoStem as “the work proposed in this application has the potential to dramatically change the way in which osteoporosis and bone fracture is treated in the military and in the general populatio.”

Read More